The request is energizing scientists investigating autistic people who largely don’t communicate with spoken words.

This month’s issue of the Null and Noteworthy newsletter breaks down some negative results involving prenatal exposures, an experimental treatment for Angelman syndrome, and the role that age at autism diagnosis plays in subsequent outcomes, and more.

A new technique to map the entire body of a mouse and a high-resolution 4D imaging method for living brain tissue samples piqued researchers’ interest on social media this week — that and more in this issue of Community Newsletter.

The University of Maryland found the papers included some data without participant consent.

An experimental drug improves sensory sensitivities in fragile X model mice — but only if it’s administered after certain brain circuits have formed, according to a new unpublished study.

The variants are associated with slight differences in measures of intelligence, income and employment, but the relationship may not be causal.

As acetaminophen lawsuits make their way through the U.S. court system, researchers reevaluate the quality of the evidence linking in-utero exposure to the painkiller to neurodevelopmental issues in children.

Contrary to conventional wisdom, most people with fragile X syndrome express the FMR1 gene — albeit improperly.

But multiple independent researchers say they are not convinced by its results, which fail to confirm high-profile findings from 2017.

This week on social media, researchers discussed sample size in neuroimaging studies and the potential of antisense oligonucleotides to restore the protein lost in fragile X syndrome.